Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%

FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies

Akums posts strong FY26 performance as EBITDA surges 61.6% in Q4

Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods

Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals

Roche launches three new Factor Xa inhibitor coagulation tests

The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention

AstraZeneca Pharma India receives permission to import new drug

The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals

Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors

Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding